---
document_datetime: 2026-01-23 13:58:07
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/nexviadyme-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: nexviadyme-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.2371209
conversion_datetime: 2026-01-26 20:50:03.168075
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.70.0
  docling-core: 2.60.2
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Nexviadyme

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                          |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------|
| Variation type IB /  | C.I.11 Introduction of, or change(s) to, the | 23/01/2026                          | N/A                                         |                                  | To Update the RMP by revising the milestones for |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000321293   | obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Change in due date for category 1, 2 or 3 studies in the RMP and/or Annex II - Accepted C.I.11.z (Type IB) - To Update the RMP by revising the milestones for the PASS category 3 SAVANT/OBS17445 study: the interim report is moved from Q4 2027 to Q4 2026, and the final study report from Q4 2029 to Q3 2028. Additionally, an amended protocol is submitted.   | the PASS category 3 SAVANT/OBS17445 study: the interim report is moved from Q4 2027 to Q4 2026, and the final study report from Q4 2029 to Q3 2028. Additionally, an amended protocol is submitted.   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|